Technologies Found (8)
Advanced Search
Array ( [cache_time] => 0 [counts_time] => 0 [query_time] => [category_counts_time] => 0 [total_time] => 0 )
Technology NameBriefcaseLead Researcher
Background Degenerative diseases become prominent with progressive ageing and thus present the most urgent biomedical challenge facing developed countries to date. One of the most prevalent musculoskeletal diseases caused during aging ...
More
Dvir-Ginzberg Mona
Background Cystic Fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. There is no known cure for cystic fibrosis and the average life expectancy is between 42 and 50 years ...
More
Steinberg Doron
  Highlights: CBD is a highly lipophilic molecule   and therefore the preparation of cannabinoid-containing non- alcoholic beverages requires in general the use of various and important concentrations of additives.  We found a new technology ...
More
Touitou Elka
Keywords Cannabis, THC, CBD, Medical Cannabis, Marijuana, Cannabinoids Current development stage TRL1 – Basic principles formulated Application The most common type of cannabinoids is tetrahydrocannabinol (THC) which ensures a psychedelic ...
More
Rabinowitch Haim
Background Bacteria communicate and coordinate population behavior through the mechanism of quorum sensing (QS), which controls the expression of genes that affect a variety of bacterial processes. Cannabis, Cannabinoids and endo-cannabinoids ...
More
Steinberg Doron
Background  Micro-emulsions are formed more or less spontaneously when their components are brought into contact.  They have been the only successful delivery systems for certain types of pharmaceutical compounds, particularly compounds such as ...
More
Domb Abraham
Prof. Yaron Ilan, Department of Human Nutrition and Metabolism and Liver Unit Hadassah Hospital Background To date, there is no effective treatment of liver diseases with the related Hepatic-Encephalopathy symptoms. It is established that ...
More
Avraham Yosefa
Background Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders. CB1 agonists (such as the ...
More
Mechoulam Raphael